❮ Back to Researchers

Dan Werb

PhD

Scientist

Email: Daniel.Werb@unityhealth.to
Twitter: @dmwerb

Research Programs

Biography

Dan Werb, PhD, is an epidemiologist and policy analyst with expertise in overdose, Human Immunodeficiency Virus (HIV), addictions, and drug policy. Dr. Werb is a Research Scientist at the Li Ka Shing Knowledge Institute (LKSKI) at St. Michael’s Hospital in Toronto. He is also an Assistant Professor in the Division of Infectious Diseases & Global Public Health at the University of California, San Diego. Dr.Werb is Director of the Centre on Drug Policy Evaluation, a recognized global leader in cutting edge policy research and communications. Dr. Werb has published dozens of studies on issues related to health policy and addictions, with a focus on preventing the transition of street youth into injection drug use, as well as on identifying the impact of policy and public health interventions on street-based drug-using populations.

Please note: Dr. Werb is not taking any summer students.

 

Recent Publications

  1. Kennedy, R, Bouck, Z, Werb, D, Kurmanalieva, A, Blyum, A, Shumskaya, N et al.. A cross-sectional assessment of injection of "salts" and HIV transmission-related behaviours among a cohort of people who inject drugs in Kyrgyzstan. J Int AIDS Soc. 2024;27 (7):e26247. doi: 10.1002/jia2.26247. PubMed PMID:38978392 PubMed Central PMC11231446.
  2. Mitra, S, Bouck, Z, Larney, S, Zolopa, C, Høj, S, Minoyan, N et al.. The impact of the COVID-19 pandemic on people who use drugs in three Canadian cities: a cross-sectional analysis. Harm Reduct J. 2024;21 (1):94. doi: 10.1186/s12954-024-00996-x. PubMed PMID:38750575 PubMed Central PMC11097551.
  3. Moran, L, Ondocsin, J, Outram, S, Ciccarone, D, Werb, D, Holm, N et al.. How do we understand the value of drug checking as a component of harm reduction services? A qualitative exploration of client and provider perspectives. Harm Reduct J. 2024;21 (1):92. doi: 10.1186/s12954-024-01014-w. PubMed PMID:38734643 PubMed Central PMC11088080.
  4. Greenwald, ZR, Werb, D, Feld, JJ, Austin, PC, Fridman, D, Bayoumi, AM et al.. Validation of case-ascertainment algorithms using health administrative data to identify people who inject drugs in Ontario, Canada. J Clin Epidemiol. 2024;170 :111332. doi: 10.1016/j.jclinepi.2024.111332. PubMed PMID:38522754 .
  5. Rammohan, I, Gaines, T, Scheim, A, Bayoumi, A, Werb, D. Overdose mortality incidence and supervised consumption services in Toronto, Canada: an ecological study and spatial analysis. Lancet Public Health. 2024;9 (2):e79-e87. doi: 10.1016/S2468-2667(23)00300-6. PubMed PMID:38307685 .
  6. Salvalaggio, G, Brooks, H, Caine, V, Gagnon, M, Godley, J, Houston, S et al.. Flawed reports can harm: the case of supervised consumption services in Alberta. Can J Public Health. 2023;114 (6):928-933. doi: 10.17269/s41997-023-00825-x. PubMed PMID:37930628 PubMed Central PMC10661131.
  7. Bowles, J, Mansoor, M, Werb, D, Kerr, T, Bardwell, G. A qualitative assessment of tablet injectable opioid agonist therapy (TiOAT) in rural and smaller urban British Columbia, Canada: Motivations and initial impacts. J Subst Use Addict Treat. 2024;157 :209185. doi: 10.1016/j.josat.2023.209185. PubMed PMID:37865289 .
  8. Gaines, TL, Werb, D, Harris, O. Young, Black/African American, and Latino communities are left behind despite legislative efforts in California to reduce HIV/STI disparities. Front Reprod Health. 2023;5 :1179334. doi: 10.3389/frph.2023.1179334. PubMed PMID:37779638 PubMed Central PMC10538965.
  9. Karamouzian, M, Rafat, B, Kolla, G, Urbanoski, K, Atkinson, K, Bardwell, G et al.. Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: A qualitative analysis. Int J Drug Policy. 2023;120 :104157. doi: 10.1016/j.drugpo.2023.104157. PubMed PMID:37574645 .
  10. Guise, A, Harris, M, McCusker, M, McNeil, R, Werb, D. Stigma is stopping an evidence based response to drug overdose deaths in the UK. BMJ. 2023;382 :e074934. doi: 10.1136/bmj-2023-074934. PubMed PMID:37558236 .
Search PubMed

Affiliations & Other Activities

  • Assistant Professor, Division of Global Public Health, University of California San Diego Director, International Centre for Science in Drug Policy